# Clobazam in Subjects With Lennox-Gastaut Syndrome

> **NCT00162981** · PHASE2 · COMPLETED · sponsor: **Lundbeck LLC** · enrollment: 68 (actual)

## Conditions studied

- Epilepsy
- Epilepsy, Generalized
- Seizures

## Interventions

- **DRUG:** Clobazam Low Dose
- **DRUG:** Clobazam High Dose

## Key facts

- **NCT ID:** NCT00162981
- **Lead sponsor:** Lundbeck LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-08
- **Final completion:** 2006-10
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2012-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162981, "Clobazam in Subjects With Lennox-Gastaut Syndrome". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00162981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*